Immunological aspects of the lethal HIV / COVID-19 coinfected cohort

   SARS-CoV-2 pandemic is now a global medical and social problem. Little is known about its impact on some vulnerable subgroups, such as immunocompromised patients. Therefore, there is still a strong interest in exploring the impact of SARS-CoV-2 infection among HIV-positive individuals worldwide.
   Aim of the study: to analyze immunological aspects of the deceased patients with HIV/COVID-19 coinfection.
   Materials and methods. We provided retrospective analysis of 258 patient’s electronic medical records. All patients were admitted to the Infectious diseases hospital № 2 with HIV / COVID-19 coinfection and died in May 2020 – February 2022. Standard immunological parameters were analyzed like CD4+, CD8+ counts and immunoregulatory index for different patient’s subgroups. Statistical data processing was provided by SPSS 17 version (allowable error E = 5 %).

   Results and discussion. The study demonstrated CD4+ and CD8+ reduction in HIV-infected with COVID-19. Late HIV-presenters didn’t display such phenomenon probably because of immune system exhaustion. COVID-19 itself in some cases could lead to immunodeficiency worsening due to depletion of T cell populations in HIV-patients on effective antiretroviral therapy.
   Conclusion. Comprehension of different immunological characteristics in HIV / COVID-19 coinfected patients could improve therapeutic approaches for this challenging cohort.

1. UNAIDS data 2021. 2021.

2. Kerkhoff A. D., Havlir D. V. CROI 2021 : Tuberculosis, Opportunistic Infections, and COVID-19 Among People with HIV // Top. Antivir. Med. 2021. Vol. 29, № 2. P. 344–351. PMID: 34107204. PMCID: PMC8224244

3. Wu M. et al. Risk of SARS-CoV-2 Infection Among People Living With HIV in Wuhan, China // Front. Public Heal. 2022. Vol. 10, № April. P. 1–7. PMID: 35570882. PMCID: PMC9099221. DOI: 10.3389/fpubh.2022.833783

4. Lee K. W. et al. COVID-19 in People Living with HIV: A Systematic Review and Meta-Analysis // Int. J. Environ. Res. Public Health. 2021. Vol. 18, № 7. PMID: 33808066. PMCID: PMC8037457. DOI: 10.3390/ijerph18073554

5. Vizcarra P., Pérez-Elías M. J., Quereda C., Moreno A., Vivancos M. J., Dronda F C.J. C.-19 I. T. Description of COVID-19 in HIV-infected individuals : a single-centre, prospective cohort // Lancet HIV. 2020. Vol. 7, № January. P. : e554–564. PMID: 32473657. PMCID: PMC7255735. DOI: 10.1016/S2352-3018(20)30164-8

6. Danwang C. et al. Outcomes of patients with HIV and COVID - 19 co-infection : a systematic review and meta-analysis // AIDS Res. Ther. BioMed Central, 2022. Vol. 19, № 3. P. 1–12. PMID: 35031068. PMCID: PMC8759058. DOI: 10.1186/s12981-021-00427-y

7. Ssentongo P. et al. Epidemiology and outcomes of COVID-19 in HIV-infected individuals : a systematic review and meta-analysis // Sci. Rep. Nature Publishing Group UK, 2021. P. 1–12. PMID: 33737527. PMCID: PMC7973415. DOI: 10.1038/s41598-021-85359-3

8. Liang Ning Luo Mafeng Chen Chunna Chen Shivank Singh Shantanu Singh Shifan Tan M. Prevalence and Mortality due to COVID-19 in HIV Co-Infected Population: A Systematic Review and Meta-Analysis // Infect. Dis. Ther. Vol. 10. PMID: 33939121. PMCID: PMC8091145. DOI: 10.1007/s40121-021-00447-1

9. Lesko C. R., Bengtson A. M. HIV and COVID-19 : Intersecting Epidemics With Many Unknowns // Am. J. Epidemiol. 2021. Vol. 190, № 1. P. 10–16. PMID: 32696057. PMCID: PMC7454306. DOI: 10.1093/aje/kwaa158

10. Zhang W. et al. The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): The Perspectives of clinical immunologists from China // Clin. Immunol. 2020. Vol. 214, № January. PMID: 32222466. PMCID: PMC7102614. DOI: 10.1016/j.clim.2020.108393

11. Paces J. et al. COVID-19 and the immune system // Physiol. Res. 2020. Vol. 69. P. 379–388. PMID: 32469225. PMCID: PMC8648321. DOI: 10.33549/physiolres.934492

12. Chang M. Fighting COVID-19 exhausts T cells // Nat. Rev. Immunol. 2020. Vol. 19, № 4. P. 4–7. PMID: 32249845. PMCID: PMC7132550. DOI: 10.1038/s41577-020-0304-7

13. Shi Y. et al. COVID-19 infection: the perspectives on immune responses // Cell Death Differ. Springer US, 2020. Vol. 27, № 5. P. 1451–1454. PMID: 32205856. PMCID: PMC7091918. DOI: 10.1038/s41418-020-0530-3

14. Sette A. and Crotty S. Adaptive immunity to SARS-CoV-2 and COVID-19 // Cell. 2020. Vol. 184. P. 861–880. PMID: 33497610. PMCID: PMC7803150. DOI: 10.1016/j.cell.2021.01.007

15. Vremennyye metodicheskiye rekomendatsii. Profilaktika, diagnostika i lechenie novoy koronavirusnoy infektsii (COVID-19). Versii 1-15. 2020-2022гг.[Interim guidelines. Prophylaxis, diagnostics and treatment of novel coronaviral infection (COVID-19). Versions 1-15. 2020-2022], https://minzdrav.gov.ru/ministry/med_covid19 (in Russian).

16. EACS. October 2021 // Journal of Nature, Science & Technology. 2021. Vol. 1, № 4. 0–148 p.

17. Clinical Info, HIV Info. GLOSSARY of HIV/AIDS-Related Terms : Offering information on HIV / AIDS treatment, prevention, and research. 2021. 1–202 p.